EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Transcatheter Tricuspid Valve Replacement in Patients After Prior Left‐Sided Valve Surgery: A Multicenter Retrospective Analysis

Tianyuan Xiong, Yi Zhang, Fan Qiao, Yuan Feng, Zhengang Zhao, Xin Wei, Xi Li, Fei Chen, Xingyu Ji, Junbo Ge, Fanglin Lu, Mao Chen

Journal of Interventional Cardiology · 2026-01 · 2026 (1)

DOI: 10.1155/joic/8817783 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Interventional Cardiology, online erschienen am 16.07.2026. Verfasst von Tianyuan Xiong und 11 weiteren Autor:innen. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Sichuan University, Sichuan Province Science and Technology Support Program.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Functional tricuspid regurgitation (TR) after previous left‐sided valve surgery (LSVS) represents a significant proportion of all isolated TR cases; tricuspid valve reoperation in such patients, often in the advanced stage of disease, is historically regarded as high‐risk. Percutaneous transcatheter–based therapies for TR emerge as a potential solution. We sought to verify the performance of the LuX‐Valve Plus system in patients with a history of LSVS.

Methods

A post hoc analysis of patients enrolled in the first‐in‐man and confirmatory study and an investigator‐initiated trial of the LuX‐Valve Plus system was conducted. Multiple endpoints, including mortality, valve performance, and functional status, were compared between patients with or without a history of LSVS. Propensity score matching (PSM) was used to minimize baseline differences between groups.

Results

The study included 153 patients, with 56 patients having prior LSVS. After PSM, there were a total of 46 matched pairs. All‐cause mortality at 6 months was similar between groups (2.38% vs. 0%, respectively). Less‐than‐moderate paravalvular leakage and central TR were consistently observed in approximately 85% and 95% of patients through 6 months. Patients after prior LSVS achieved similar functional outcome in terms of the proportion of patients in NYHA Class I–II at 6 months (81.25% vs. 95.83%, p = 0.221). The Kansas City Cardiomyopathy Questionnaire score improved significantly after the procedure.

Conclusions

In this small‐scale study, transcatheter implantation of the LuX‐Valve Plus for TR appeared to be safe and effective in patients with a history of LSVS, showing lower short‐term mortality and a degree of TR correction comparable to surgical outcomes.

Förderung

  • National Natural Science Foundation of China
  • Sichuan University
  • Sichuan Province Science and Technology Support Program

Zitieren

APA

Xiong, T., Zhang, Y., Qiao, F., Feng, Y., Zhao, Z., Wei, X., Li, X., Chen, F., Ji, X., Ge, J., Lu, F., & Chen, M. (2026). Transcatheter Tricuspid Valve Replacement in Patients After Prior Left‐Sided Valve Surgery: A Multicenter Retrospective Analysis. Journal of Interventional Cardiology, 2026(1). https://doi.org/10.1155/joic/8817783

Vancouver

Xiong T, Zhang Y, Qiao F, Feng Y, Zhao Z, Wei X, et al. Transcatheter Tricuspid Valve Replacement in Patients After Prior Left‐Sided Valve Surgery: A Multicenter Retrospective Analysis. Journal of Interventional Cardiology. 2026;2026(1). doi:10.1155/joic/8817783

BibTeX
@article{Xiong2026,
  author = {Xiong, Tianyuan and Zhang, Yi and Qiao, Fan and Feng, Yuan and Zhao, Zhengang and Wei, Xin and Li, Xi and Chen, Fei and Ji, Xingyu and Ge, Junbo and Lu, Fanglin and Chen, Mao},
  title = {Transcatheter Tricuspid Valve Replacement in Patients After Prior Left‐Sided Valve Surgery: A Multicenter Retrospective Analysis},
  journal = {Journal of Interventional Cardiology},
  year = {2026},
  volume = {2026},
  number = {1},
  doi = {10.1155/joic/8817783}
}
Kostenlos starten →